➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
AstraZeneca
Dow
Mallinckrodt
McKinsey

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Desvenlafaxine succinate - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for desvenlafaxine succinate and what is the scope of patent protection?

Desvenlafaxine succinate is the generic ingredient in two branded drugs marketed by Actavis Labs Fl, Alembic Pharms Ltd, Casi Pharms Inc, Hikma, Intellipharmaceutics, Lupin Ltd, Mylan, Yichang Humanwell, Zydus Pharms, and Pf Prism Cv, and is included in eleven NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Desvenlafaxine succinate has sixty-eight patent family members in thirty-two countries.

There are sixteen drug master file entries for desvenlafaxine succinate. Eighteen suppliers are listed for this compound.

Recent Clinical Trials for desvenlafaxine succinate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Korea Cancer Center HospitalPhase 4
Seoul National University Bundang HospitalPhase 4

See all desvenlafaxine succinate clinical trials

Medical Subject Heading (MeSH) Categories for desvenlafaxine succinate
Paragraph IV (Patent) Challenges for DESVENLAFAXINE SUCCINATE
Tradename Dosage Ingredient NDA Submissiondate
PRISTIQ TABLET, EXTENDED RELEASE;ORAL desvenlafaxine succinate 021992 2015-05-08
PRISTIQ TABLET, EXTENDED RELEASE;ORAL desvenlafaxine succinate 021992 2012-02-29

US Patents and Regulatory Information for desvenlafaxine succinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No   Start Trial   Start Trial   Start Trial
Actavis Labs Fl DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204065-002 Jul 29, 2016 AB RX No No   Start Trial   Start Trial   Start Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Lupin Ltd DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204172-002 Jun 29, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Intellipharmaceutics DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204805-002 May 7, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Johnson and Johnson
AstraZeneca
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.